on The Vanguard Group, Inc. (isin : US12572Q1058)
Vanguard Group Discloses Stake in Avadel Pharmaceuticals
The Vanguard Group, Inc. has filed Form 8.3 with the Irish Takeover Panel, disclosing its position in Avadel Pharmaceuticals plc. As of November 6, 2025, Vanguard holds 5,523,410 ordinary shares, representing a 5.67% stake in Avadel.
This disclosure highlights Vanguard’s interest in relevant securities of Avadel, a requirement under the Irish Takeover Panel's rules for entities holding a position of 1% or more. The filing also notes recent transactions: the purchase of 462 shares and the sale of 396 shares, both at $18.71 per share.
No cash-settled derivative positions or agreements related to these securities were indicated. Furthermore, Vanguard reported no indemnity or dealing arrangements associated with Avadel securities.
R. H.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all The Vanguard Group, Inc. news